The binding of CD40 to the CD40 ligand expressed on CD4+ helper T cells results in activation of antigen‐presenting cells.57 Furthermore, triggering CD40 has been shown to enhance the efficacy of vaccines in promoting anti‐tumor immunity.57 These findings led to the hypothesis that anti‐CD40 agonist mAb therapy could be used in conjunction with chemotherapy as a novel treatment for pancreatic cancer.58 The gene discussed is CD40; the disease is familial pancreatic carcinoma.